Top Japan Pharma Stocks to Watch: Jefferies Highlights Buying Opportunities

Jefferies analysts view recent price declines in major Japanese pharmaceutical stocks, including Sumitomo Pharma, Otsuka Holdings, and Daiichi Sankyo, as compelling buying opportunities ahead of multiple near-term catalysts. The firm maintains "Buy" ratings, citing strong anticipated earnings reports, potential regulatory approvals for key pipeline assets, and significant milestone payments expected to drive positive performance through year-end, with JPMorgan also upgrading Sumitomo Pharma to Overweight.

Analysis

Jefferies analysts have identified a compelling tactical opportunity in select Japanese pharmaceutical stocks, asserting that recent price declines have created attractive entry points ahead of multiple near-term catalysts. Specifically, Sumitomo Pharma (4506 JP), which fell 3.5% on Friday, is highlighted due to anticipated strong first-half results on October 31, driven by better-than-expected sales of its cancer treatment Orgovyx and a substantial milestone payment expected from Pfizer. This bullish view is reinforced by a recent JPMorgan upgrade of Sumitomo to 'Overweight' from 'Neutral'. Similarly, Otsuka Holdings (4578 JP) saw a 2.9% drop, which Jefferies views as an opportunity preceding its third-quarter results on October 31 and a series of significant pipeline events, including a likely application for its lung cancer drug Zipalertinib, a key CMS reimbursement ruling in October, and a potential FDA approval for Sibeprenlimab on November 28. Daiichi Sankyo (4568 JP) is also flagged as a 'Buy' following its recent share price weakness, with catalysts including new data at the ESMO conference, an explanatory meeting on October 21, and strong first-half results expected on October 31. The consistent theme is a market dislocation where recent negative price action appears misaligned with a slate of potentially positive fundamental and regulatory events scheduled before year-end.

Key Decisions for Investors

• Investors could consider initiating or increasing positions in Sumitomo Pharma, Otsuka Holdings, and Daiichi Sankyo to capitalize on potential price appreciation leading into a series of specified catalysts.
• Closely monitor the earnings reports for all three companies on October 31, as well as key regulatory and clinical milestones such as the CMS ruling for Otsuka in October and data from Daiichi Sankyo's ESMO presentation on October 21.
• The opportunity is time-sensitive and catalyst-driven; the investment thesis hinges on positive outcomes from these events, so any negative developments in earnings, clinical data, or regulatory decisions would represent a significant risk to short-term performance.